Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Röttinger

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
MMW, Munchener Medizinische Wochenschrift|March 5, 1982
[Neglected otorhinolaryngologic tumors]E Röttinger
Developmental Biology|April 7, 2011
Ventralization of an indirect developing hemichordate by NiCl₂ suggests a conserved mechanism of dorso-ventral (D/V) patterning in Ambulacraria (hemichordates and echinoderms)E Röttinger, M Q Martindale
Cancer Chemotherapy and Pharmacology|January 1, 1992
Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitroD Bartkowiak, J Hemmer, E Röttinger
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2004
Guidelines for the infrastructure of training institutes and teaching departments for radiotherapy in EuropeE Röttinger, A Barrett, J W Leer, et al.
Strahlentherapie|October 1, 1985
Opto-electronic patient positioningE Röttinger, E Schneider, P Blank, et al.
Cancer|August 1, 1991
The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigenF Safi, I Kohler, E Röttinger, et al.
MMW, Munchener Medizinische Wochenschrift|March 30, 1979
[Prevention of metastases: wishful thinking or possibility?]H Gastpar, E Krokowski, E Röttinger, et al.
The International Journal of Biological Markers|October 1, 1989
Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancerF Safi, I Kohler, E Röttinger, et al.
Langenbeck'S Archives of Surgery|January 28, 1999
Adjuvant radiochemotherapy--what is the patients benefit?K H Link, L Staib, M Schatz, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 9, 1999
Multimodal therapy in rectal cancerK H Link, L Staib, M Schatz, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
MMW, Munchener Medizinische Wochenschrift|March 5, 1982
[Neglected otorhinolaryngologic tumors]E Röttinger
Developmental Biology|April 7, 2011
Ventralization of an indirect developing hemichordate by NiCl₂ suggests a conserved mechanism of dorso-ventral (D/V) patterning in Ambulacraria (hemichordates and echinoderms)E Röttinger, M Q Martindale
Cancer Chemotherapy and Pharmacology|January 1, 1992
Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitroD Bartkowiak, J Hemmer, E Röttinger
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2004
Guidelines for the infrastructure of training institutes and teaching departments for radiotherapy in EuropeE Röttinger, A Barrett, J W Leer, et al.
Strahlentherapie|October 1, 1985
Opto-electronic patient positioningE Röttinger, E Schneider, P Blank, et al.
Cancer|August 1, 1991
The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigenF Safi, I Kohler, E Röttinger, et al.
MMW, Munchener Medizinische Wochenschrift|March 30, 1979
[Prevention of metastases: wishful thinking or possibility?]H Gastpar, E Krokowski, E Röttinger, et al.
The International Journal of Biological Markers|October 1, 1989
Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancerF Safi, I Kohler, E Röttinger, et al.
Langenbeck'S Archives of Surgery|January 28, 1999
Adjuvant radiochemotherapy--what is the patients benefit?K H Link, L Staib, M Schatz, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 9, 1999
Multimodal therapy in rectal cancerK H Link, L Staib, M Schatz, et al.
Pageof 2